Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...

In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a condition in the cornea that subsequently bears his name. The patients ...

The persistent corneal edema market is experiencing steady growth, driven by rising clinical awareness, improved postoperative monitoring, and growing focus on endothelial dysfunction-related ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Please provide your email address to receive an email when new articles are posted on . Many years of research led to the approval of a breakthrough cell therapy for corneal endothelial dysfunction in ...

CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...

The correct diagnosis is iridocorneal endothelial (ICE) syndrome. ICE syndrome should be in the differential diagnosis for any young to middle-aged adult who presents with an acquired unilateral ...